Cargando…

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report

A 70‐year‐old woman with type 2 diabetes was admitted to Gifu University Hospital, Gifu, Japan, because of ketosis. She was diagnosed with type 2 diabetes at age 49 years and started insulin therapy at age 57 years, which restored glycemic control. Insulin therapy was discontinued and oral antidiabe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yasuda, Megumi, Iizuka, Katsumi, Kato, Takehiro, Liu, Yanyan, Takao, Ken, Nonomura, Kenta, Mizuno, Masami, Yabe, Daisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232287/ https://www.ncbi.nlm.nih.gov/pubmed/31479586 http://dx.doi.org/10.1111/jdi.13137

Ejemplares similares

SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
por: Nonomura, Kenta, et al.
Publicado: (2020)

Diagnosis and treatment of primary central nervous system lymphoma with the primary lesion in the hypothalamus: a case report
por: Takao, Ken, et al.
Publicado: (2021)

A novel RFX6 heterozygous mutation (p.R652X) in maturity‐onset diabetes mellitus: A case report
por: Imaki, Sakiho, et al.
Publicado: (2021)

ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue
por: Iizuka, Katsumi, et al.
Publicado: (2020)

Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
por: Sasaki, Takashi
Publicado: (2018)

Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
por: Sakai, Mayu, et al.
Publicado: (2022)

Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment
por: Tsukada, Daichi, et al.
Publicado: (2022)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

A case of familial hypocalciuric hypercalcemia type 1 due to CASR p.Pro55Leu mutation
por: Sumida, Akira, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients
por: Ohashi, Naro, et al.
Publicado: (2020)

ChREBP Reciprocally Regulates Liver and Plasma Triacylglycerol Levels in Different Manners
por: Iizuka, Katsumi, et al.
Publicado: (2018)

A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes
por: Kubota, Sodai, et al.
Publicado: (2020)

Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial
por: Iizuka, Katsumi, et al.
Publicado: (2021)

The Role of Metagenomics in Precision Nutrition
por: Iizuka, Katsumi, et al.
Publicado: (2020)

Dietary and Nutritional Guidelines for People with Diabetes
por: Iizuka, Katsumi, et al.
Publicado: (2023)

ChREBP-Knockout Mice Show Sucrose Intolerance and Fructose Malabsorption
por: Kato, Takehiro, et al.
Publicado: (2018)

A Low-Carbohydrate Diet Improves Glucose Metabolism in Lean Insulinopenic Akita Mice Along With Sodium-Glucose Cotransporter 2 Inhibitor
por: Fujita, Yukihiro, et al.
Publicado: (2020)

iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial
por: Yabe, Daisuke, et al.
Publicado: (2021)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

In Reply to “Letter Regarding ‘Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis’”
por: Anan, Go, et al.
Publicado: (2023)

Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy
por: Nagai, Yoshio, et al.
Publicado: (2019)

A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
por: Sargeant, Jack Alistair, et al.
Publicado: (2019)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
por: Ansary, Tuba M., et al.
Publicado: (2019)

Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome
por: Nagashima, Shuichi, et al.
Publicado: (2020)

Case report of superior mesenteric artery syndrome that developed in a lean type 2 diabetes patient and was associated with rapid body weight loss after sodium–glucose cotransporter 2 inhibitor administration
por: Hirai, Taro, et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice
por: Murashima, Miho, et al.
Publicado: (2021)

Lean nonalcoholic fatty liver disease and sarcopenia
por: Chen, Milian, et al.
Publicado: (2023)

Effects of Sodium Glucose Cotransporter 2 Inhibitor on Renal Renin-Angiotensin-Aldsoterone System
por: Takeda, Yoshiyu, et al.
Publicado: (2021)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_of730p3o3eant70776ibijah6q